脾酪氨酸激酶 (SYK) 是一种非受体酪氨酸激酶，已成为癌细胞生存和分裂的复杂交响乐中的重要组成部分。 SYK 激活（组成型）在多种 B 细胞恶性肿瘤中均有记录，其抑制会诱导程序性细胞死亡。在某些情况下，它还充当肿瘤抑制因子。 SYK 参与癌症生长，特别是慢性淋巴细胞白血病 (CLL)、弥漫性大 B 细胞淋巴瘤 (DLBCL)、急性髓系白血病 (AML) 和讨论了多发性骨髓瘤（MM）。还涵盖了针对癌症的 SYK 治疗策略，包括研究中的 SYK 抑制剂、SYK 抑制剂与其他针对治疗相关靶点的药物的组合，以及构建新的 SYK 抑制剂结构组合的最新进展。SYK 抑制剂领域目前受到以下因素的损害： SYK抑制剂从临床前研究到临床研究的转化率很低。此外，与 SYK 抑制剂的应用相关的剂量限制毒性也已得到证实。因此，开发新的SYK抑制结构模板已迫在眉睫。为了实现上述目标，跨学科团队应不断投入努力，扩大 SYK 抑制剂库的规模。

Spleen tyrosine kinase (SYK), a nonreceptor tyrosine kinase, has emerged as a vital component in the complex symphony of cancer cell survival and division. SYK activation (constitutive) is documented in various B-cell malignancies, and its inhibition induces programmed cell death. In some instances, it also acts as a tumor suppressor.Involvement of the SYK in the cancer growth, specifically in the progression of chronic lymphocytic leukemia (CLL), diffuse large B cell lymphomas (DLBCLs), acute myeloid leukemia (AML), and multiple myeloma (MM) is discussed. Therapeutic strategies to target SYK in cancer, including investigational SYK inhibitors, combinations of SYK inhibitors with other drugs targeting therapeutically relevant targets, and recent advancements in constructing new structural assemblages as SYK inhibitors, are also covered.The SYK inhibitor field is currently marred by the poor translation rate of SYK inhibitors from preclinical to clinical studies. Also, dose-limited toxicities associated with the applications of SYK inhibitors have been evidenced. Thus, the development of new SYK inhibitory structural templates is in the need of the hour. To accomplish the aforementioned, interdisciplinary teams should incessantly invest efforts to expand the size of the armory of SYK inhibitors.